Abstract
Meeting abstracts Single-agent Cetuximab has been shown to improve objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) in patients (pts) with epidermal growth factor receptor (EGFR) expressing, KRAS wild-type (WT) metastatic colorectal cancer (mCRC) who failed
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have